About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main objectives are to improve the diagnosis of immunodeficiencies and autoimmune diseases, addressing also their heterogeneity and mechanisms in close collaboration with the pediatrics, thyroid and systemic disease groups, being internationally recognized in both areas. The group participates in numerous research projects at the Vall d'Hebron Barcelona Hospital Campus that use immunological tests developed for specific projects led by the kidney transplantation, intensive care medicine, internal medicine, allergy and rheumatology groups. During the COVID pandemic the group made contributions in improving the immunogenetic and immunological risk profiles and in the evaluation of the immune response to vaccination and natural infection, collaborating with national and international networks. The group has also generated a biobank of more than 8.000 samples from patients with COVID-19 that have been incorporated into the VHIR biobank.
The group works as a coordinator of the "Focis" Center of Excellence (Federation of Clinical Immunology Societies) of Barcelona.
IP: Ingrid Johana Gil Serrano Collaborators: - Funding agency: Stat. Catalana d'Al·lèrgia i Immunologia Clínica Funding: 9000 Reference: SCAIC/BEQUES/2020/GIL Duration: 01/06/2020 - 01/01/2025
IP: Juan Jose Gonzalez Lopez Collaborators: Manuel Hernández González, Jose Angel Rodrigo Pendás, Maria Belén Viñado Perez, Aina Aguiló Cucurull, Alba Mir Cros, Albert Moreno Mingorance, Andrea Martín Nalda, Nuria Serre Delcor, Josep Roca Grande, Laura Batlle Masó Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI21/00132 Duration: 01/01/2022 - 30/06/2026
IP: OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE Collaborators: OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE , Gloria Inés Iacoboni García-Calvo, Maria Queralt Gorgas Torner, Lucas Rivera Sánchez, Anna Maria Farriols Danes, Pere Barba Suñol, Carla Alonso Martinez, Janire Perurena Prieto, Maria Josep Carreras Soler, Cecilia Carmen Carpio Segura Funding agency: Instituto de Salud Carlos III Funding: 111320 Reference: PI21/00197 Duration: 01/01/2022 - 31/12/2024
A Vall d’Hebron team demonstrates, for the first time, the potential of optical genome mapping to detect genetic alterations associated with this rare disease that are not identified using conventional methods.
The study describes the first documented case worldwide of hereditary angioedema transmission through assisted reproduction.
The paper describes the case of a patient in whom, years after a bone marrow transplant, two immune cell lines corrected the original genetic defect.
